Similar analyses conducted in chronic lymphocytic leukemia (CLL), where DNA from tumor CD19+CD5+ lymphocytes and non-tumor cells were compared, also identified mutations affecting the control of splicing mechanisms [5,6] indicating that similar mutations could be observed in both myeloid and lymphoid neoplasms [7, 8]. This evidence concerns the gene CD19 and neoplasm.